INDIVIOR PLC/ GB00BN4HT335 /
2024-04-24 5:29:50 PM | Chg. +13.00 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
1,520.00GBX | +0.86% | 16,241 Turnover(GBP): 247,195.3100 |
-Bid Size: - | -Ask Size: - | 2.08 bill.GBP | - | - |
GlobeNewswire
04-18
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
04-11
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18,...
GlobeNewswire
04-03
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Mod...
GlobeNewswire
03-05
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
01-31
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
GlobeNewswire
2023-11-23
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on Novem...
Newsfile Corp
2023-10-31
Pharma and Biotech Business Development Leaders to Discuss Psychedelics Partnering at Wonderland
GlobeNewswire
2023-09-06
Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
GlobeNewswire
2023-09-04
Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
GlobeNewswire
2022-03-24
Addex to Present at the Bio-Europe Spring 2022 and Maxim Group – 2022 Virtual Growth Conferences